Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate

Reproductive Sciences

Volumn 14, Issue 2, 2007, Pages 160-168

  Verheul, Herman A M ^a   Blok, Leen J ^b   Burger, Curt W ^b   Hanifi Moghaddam, Payman ^b   Kloosterboer, Helenius J ^a  

^a NV ORGANON   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Estradiol metabolites; Sulfation; Tibolone metabolites; Tissue distribution; Uterus; Vagina

Indexed keywords

ESTRADIOL; ESTRONE; MEDROXYPROGESTERONE ACETATE; TIBOLONE; 3 HYDROXYTIBOLONE; 3-HYDROXYTIBOLONE; DELTA(4) TIBOLONE; DELTA(4)-TIBOLONE; DRUG DERIVATIVE; ESTRONE SULFATE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; FEMALE; HUMAN; MYOMETRIUM; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SULFATION; TISSUE DISTRIBUTION; UTERUS PROLAPSE; VAGINA; AGED; BLOOD; DRUG EFFECT; METABOLISM; MIDDLE AGED;

AGED; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; MYOMETRIUM; NORPREGNENES; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TISSUE DISTRIBUTION; UTERINE PROLAPSE; VAGINA;

EID: 34648817105     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719106298684     Document Type: Article

References (27)

1. Kloosterboer HJ Tissue selectivity: the mechanism of action of tibolone Maturitas. 2004 ; 49: S30 - S40.
2. Timmer CJ, Houwing NS Dose proportionality of three different doses of tibolone. Pharmacotherapy. 2002 ; 22: 6-13.
3. de Gooyer ME, Deckers GH, Schoonen WGEJ, Verheul HAM, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003 ; 68: 21-30.
4. Vos Rme, Krebbers Sfm, Verhoeven Chj, Delbressine Lpc. The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002 ; 30: 106-112.
5. Tang B., Markiewicz L., Kloosterboer HJ, Gurpide E. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of steroidal drugs. J Steroid Biochem Mol Biol. 1993 ; 45: 345-351.
6. Steckelbroeck S., Jin Y., Oyesanmi B., Kloosterboer HJ, Penning TM Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldoketo reductase 1C subfamily: inversion of stereospecificity with a Delta5(10)-3- ketosteroid. Mol Pharmacol. 2004 ; 66: 1702-1711.
7. Chetrite GS, Kloosterboer HJ, Philippe J-C., Pasqualini JR Effect of Org OD14 (Livial) and its metabolites on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T47D, and the hormone-independent MDA-MB-231 breast cancer cell lines. Anticancer Res. 1999 ; 19: 269-276.
8. Falany JL, Macrina N., Falany CN Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol. 2004 ; 88: 383-391.
9. Wang M., Ebmeier CC, Olin JR, Anderson RJ Sulfation of tibolone metabolites by human postmenopausal liver and small intestine sulfotransferases (SULTs). Steroids. 2006 ; 71: 343-351.
10. de Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC, Ederveen Agh, Verheul Ham, Kloosterboer HJ Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol. 2001 ; 183: 55-62.
11. Chetrite G., Kloosterboer HJ, Pasqualini JR Effect of tibolone (Org OD14) and its metabolites on estrone sulfatase activity in MCF-7 and T47D mammary cancer cells. Anticancer Res. 1997 ; 17: 135-140.
12. Purohit A., Malini B., Hooymans C., Newman SP Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res. 2002 ; 1: 1-6.
13. Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR Effects of Org OD14 (Livial®) and its metabolites on 17βhydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and TD-47D breast cancer cells. Anticancer Res. 1999 ; 19: 261-268.
14. Hanifi-Moghaddam P., Gielen Scjp, Kloosterboer HJ, et al. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone. J Clin Endocrinol Metab. 2005 ; 90 ; 973-983.
15. Klaassens Aha, van Wijk FH, Hanifi-Moghaddam P., et al. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen-only or estrogen plus progestagen. Fertil Steril. 2006 ; 86: 352-361.
16. Anderson GL, Judd HL, Kaunitz AM, et al, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: theWomen's Health Initiative randomized trial. JAMA. 2003 ; 290: 1739-1748.
17. Pasqualini JR, Chetrite GS Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 2005 ; 93: 221-236.
18. Falany JL, Falany CN Regulation of estrogen sulfotransferase in human endometrial carcinoma cells by progesterone. Endocrinology. 1996 ; 137: 1395-1401.
19. Falany JL, Falany CN Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone. Steroids. 2006 ; 71: 880-885.
20. Voelker W., Coelingh Bennink Hjt, Helmond FA Effects of tibolone on the endometrium. Climacteric. 2001 ; 4: 203-208.
21. Davis SR The effects of tibolone on mood and libido. Menopause. 2002 ; 9: 162-170.
22. Utian WH, Shoupe D., Bachmann G., Pinkerton JV, Pickar JH Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001 ; 75: 1065-1079.
23. Traish AM, Kim N., Min K., Munarriz R., Goldstein I. Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertil Steril. 2002 ; 77: S11 - S18.
24. Lasley BL, Santoro N., Randolf JF, et al. The relationship of circulating dehydroepiandrosterone, testosterone and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab. 2002 ; 87: 3760-3767.
25. Zhang W., Mazella J., Kloosterboer HJ, Tseng L. Effects of tibolone on nuclear receptors in human endometrial cells. Am J Obstet Gynecol. 2006 ; 195: 97-102.
26. Markiewicz L., Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem. 1990 ; 35: 535-541.
27. Hanifi-Moghaddam P., Boers-Sijmons B., Klaassens Aha, van Wijk FH, den Bakker MA, Ott MC, Shipley GL, Verheul Ham, Kloosterboer HJ, Burger CW, Blok LJ Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen+ progestagen signaling. J Mol Med 2007 ; DOI 10.1007/s00109-006-0146-1.